A sensitive in-house RT-PCR genotyping system for combined detection of plasma HIV-1 and assessment of drug resistance

Journal of Virological Methods

Volumn 133, Issue 2, 2006, Pages 137-145

  Steegen, Kim ^a   Demecheleer, Els ^b   De Cabooter, Nancy ^b   Nges, Dieudonné ^c   Temmerman, Marleen ^a   Ndumbe, Peter ^c   Mandaliya, Kishor ^d   Plum, Jean ^b   Verhofstede, Chris ^a,b  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c UNIVERSITY OF YAOUNDÉ I   (Cameroon)

^d Department of Obstetrics and Gynaecology   (Kenya)

Author keywords

Genotyping; HIV 1; Qualitative detection; RT PCR

Indexed keywords

LAMIVUDINE; LOPINAVIR; NUCLEIC ACID; PROTEINASE; RNA DIRECTED DNA POLYMERASE; STAVUDINE; ZIDOVUDINE;

ARTICLE; CODON; CONTROLLED STUDY; COST; DRUG RESISTANCE; EXTRACTION; GENE AMPLIFICATION; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS DETECTION; VIRUS LOAD;

ANTI-HIV AGENTS; BASE SEQUENCE; COHORT STUDIES; COSTS AND COST ANALYSIS; DRUG RESISTANCE, VIRAL; FEMALE; GENES, VIRAL; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MUTATION; NUCLEIC ACID AMPLIFICATION TECHNIQUES; PHYLOGENY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; VIRAL LOAD;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33645305135     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2005.11.004     Document Type: Article

References (14)

1. S. Beddows, S. Galpin, S.H. Kazmi, A. Ashraf, A. Johargy, A.J. Frater, N. White, R. Braganza, J. Clarke, M. McClure, and J.N. Weber Performance of two commercially available sequence-based HIV-1 genotyping systems for the detection of drug resistance against HIV type 1 group M subtypes J. Med. Virol. 70 2003 337 342
2. P.N. Fonjungo, E.N. Mpoudi, J.N. Torimiro, G.A. Alemnji, L.T. Eno, E.J. Lyonga, J.N. Nkengasong, R.B. Lal, M. Rayfield, M.L. Kalish, T.M. Folks, and D. Pieniazek Human immunodeficiency virus type 1 group m protease in Cameroon: genetic diversity and protease inhibitor mutational features J. Clin. Microbiol. 40 2002 837 845
3. E. Fontaine, C. Riva, M. Peeters, J.C. Schmit, E. Delaporte, K. Van Laethem, K. Van Vaerenbergh, J. Snoeck, E. Van Wijngaerden, E. De Clercq, M. Van Ranst, and A.M. Vandamme Evaluation of two commercial kits for the detection of genotypic drug resistance on a panel of HIV type 1 subtypes A through J J. Acquir. Immune. Defic. Syndr. 28 2001 254 258
4. P. Gaillard, F. Mwanyumba, C. Verhofstede, P. Claeys, V. Chohan, E. Goetghebeur, K. Mandaliya, J. Ndinya-Achola, and M. Temmerman Vaginal lavage with chlorhexidine during labour to reduce mother-to-child HIV transmission: clinical trial in Mombasa, Kenya Aids 15 2001 389 396
5. G.J. Hanna, H.U. Balaguera, K.A. Freedberg, B.G. Werner, K.A. Steger, D.E. Craven, and R.T. D'Aquila Drug-selected resistance mutations and non-B subtypes in antiretroviral-naive adults with established human immunodeficiency virus infection J. Infect. Dis. 188 2003 986 991
6. L.L. Jagodzinski, J.D. Cooley, M. Weber, and N.L. Michael Performance characteristics of human immunodeficiency virus type 1 (HIV-1) genotyping systems in sequence-based analysis of subtypes other than HIV-1 subtype B J. Clin. Microbiol. 41 2003 998 1003
7. J.S. James Merck, Bristol-Myers Squibb announce major price reductions for poorest countries: major access progress but questions remain AIDS Treat. News 2001 5 7
8. D.M. Kent, D. McGrath, J.P. Ioannidis, and M.L. Bennish Suitable monitoring approaches to antiretroviral therapy in resource-poor settings: setting the research agenda Clin. Infect. Dis. 37 2003 S13 S24
9. M. Mracna, G. Becker-Pergola, J. Dileanis, L.A. Guay, S. Cunningham, J.B. Jackson, and S.H. Eshleman Performance of Applied Biosystems ViroSeq HIV-1 genotyping system for sequence-based analysis of non-subtype B human immunodeficiency virus type 1 from Uganda J. Clin. Microbiol. 39 2001 4323 4327
10. J.R. Neilson, G.C. John, J.K. Carr, P. Lewis, J.K. Kreiss, S. Jackson, R.W. Nduati, D. Mbori-Ngacha, D.D. Panteleeff, S. Bodrug, C. Giachetti, M.A. Bott, B.A. Richardson, J. Bwayo, J. Ndinya-Achola, and J. Overbaugh Subtypes of human immunodeficiency virus type 1 and disease stage among women in Nairobi, Kenya J. Virol. 73 1999 4393 4403
11. J.N. Nkengasong, W. Janssens, L. Heyndrickx, K. Fransen, P.M. Ndumbe, J. Motte, A. Leonaers, M. Ngolle, J. Ayuk, and P. Piot Genotypic subtypes of HIV-1 in Cameroon Aids 8 1994 1405 1412
12. J. Snoeck, S. Van Dooren, K. Van Laethem, I. Derdelinckx, E. Van Wijngaerden, E. De Clercq, and A.M. Vandamme Prevalence and origin of HIV-1 group M subtypes among patients attending a Belgian hospital in 1999 Virus Res. 85 2002 95 107
13. J. Snoeck, K. Van Laethem, P. Hermans, E. Van Wijngaerden, I. Derdelinckx, Y. Schrooten, D.A. van de Vijver, S. De Wit, N. Clumeck, and A.M. Vandamme Rising prevalence of HIV-1 non-B subtypes in Belgium: 1983-2001 J. Acquir. Immune. Defic. Syndr. 35 2004 279 285
14. J.W. Tang, and D. Pillay Transmission of HIV-1 drug resistance J. Clin. Virol. 30 2004 1 10